Heart failure is a significant global health issue. More than half of the people who develop heart failure die within 5 years. Current treatments do not help the largest group of these patients – those with heart failure with preserved ejection fraction (HFpEF) – and have limited effectiveness for those with reduced injection fraction (HFrEF). HFpEF has been called the greatest unmet need in cardiovascular disease given the number of heart failure deaths per year and the proportion of patients with HFpEF. Despite significant research into the drivers of heart failure, many patients remain undiagnosed or poorly managed and new therapies are needed.
This webinar, featuring a guest from Servier Pharmaceutical, covered recent advances in heart failure genomics with a focus on translating findings into improved therapeutics and diagnosis. Genuity Science is building large-scale real-world datasets combining whole-genome sequencing and detailed longitudinal clinical data from thousands of participants. For heart failure, these datasets help scientists discover and validate new drug targets for heart failure and are enriched with participants with HFpEF. Additionally, the speakers discussed what is currently known about genomic drivers of heart failure and opportunities for novel therapeutics being explored in their own research programs.
Irene Blat, PhDSenior Director of Data Products and Analytics, Genuity Science